Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for swallowing difficulties in rare genetic disease

NCT ID NCT07013292

First seen May 11, 2026 · Last updated May 24, 2026 · Updated 1 time

Summary

This study is testing whether the drug omaveloxolone can improve swallowing difficulties in people with Friedreich's ataxia, a rare nerve disease that affects movement and coordination. About 40 French patients who have been taking the drug for at least six months will fill out a questionnaire about their swallowing at the start and after six months. The goal is to see if the drug eases this common and serious symptom.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU NICE

    RECRUITING

    Nice, Alpes Maritimes, 06000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.